These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17045763)

  • 1. Opposing securin and p53 protein expression in the oxaliplatin-induced cytotoxicity of human colorectal cancer cells.
    Chiu SJ; Hsu TS; Chao JI
    Toxicol Lett; 2006 Dec; 167(2):122-30. PubMed ID: 17045763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of securin promotes colorectal cancer cell death via a p53-independent pathway after radiation.
    Chiu SJ; Hsu TS; Chao JI
    Chem Biol Interact; 2007 Dec; 170(3):153-61. PubMed ID: 17854787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depletion of securin increases arsenite-induced chromosome instability and apoptosis via a p53-independent pathway.
    Chao JI; Hsu SH; Tsou TC
    Toxicol Sci; 2006 Mar; 90(1):73-86. PubMed ID: 16338954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells.
    Liu HF; Hsiao PW; Chao JI
    Chem Biol Interact; 2008 Oct; 176(1):48-57. PubMed ID: 18760266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines.
    Atallah D; Marsaud V; Radanyi C; Kornprobst M; Rouzier R; Elias D; Renoir JM
    Int J Hyperthermia; 2004 Jun; 20(4):405-19. PubMed ID: 15204521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The blockage of survivin and securin expression increases the cytochalasin B-induced cell death and growth inhibition in human cancer cells.
    Chao JI; Liu HF
    Mol Pharmacol; 2006 Jan; 69(1):154-64. PubMed ID: 16219911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175.
    Hayward RL; Schornagel QC; Tente R; Macpherson JS; Aird RE; Guichard S; Habtemariam A; Sadler P; Jodrell DI
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):577-83. PubMed ID: 15726367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells.
    Toscano F; Parmentier B; Fajoui ZE; Estornes Y; Chayvialle JA; Saurin JC; Abello J
    Biochem Pharmacol; 2007 Aug; 74(3):392-406. PubMed ID: 17559811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel synthetic compound induces lung carcinoma cell death associated with inhibiting ERK and CDC2 phosphorylation via a p53-independent pathway.
    Hsu TS; Chen C; Lee PT; Chiu SJ; Liu HF; Tsai CC; Chao JI
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):799-808. PubMed ID: 18193228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines.
    Rakitina TV; Vasilevskaya IA; O'Dwyer PJ
    Biochem Pharmacol; 2007 Jun; 73(11):1715-26. PubMed ID: 17343830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
    Lin J; Hsiao PW; Chiu TH; Chao JI
    Biochem Pharmacol; 2005 Sep; 70(5):658-67. PubMed ID: 16004971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
    Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
    Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
    Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
    Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis.
    Bernal JA; Luna R; Espina A; Lázaro I; Ramos-Morales F; Romero F; Arias C; Silva A; Tortolero M; Pintor-Toro JA
    Nat Genet; 2002 Oct; 32(2):306-11. PubMed ID: 12355087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer.
    Yokoo S; Masuda S; Yonezawa A; Terada T; Katsura T; Inui K
    Drug Metab Dispos; 2008 Nov; 36(11):2299-306. PubMed ID: 18710896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells.
    Chiu SJ; Lee YJ; Hsu TS; Chen WS
    Chem Biol Interact; 2009 Dec; 182(2-3):173-82. PubMed ID: 19735649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling.
    Mitchell C; Kabolizadeh P; Ryan J; Roberts JD; Yacoub A; Curiel DT; Fisher PB; Hagan MP; Farrell NP; Grant S; Dent P
    Mol Pharmacol; 2007 Sep; 72(3):704-14. PubMed ID: 17578896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enniatin exerts p53-dependent cytostatic and p53-independent cytotoxic activities against human cancer cells.
    Dornetshuber R; Heffeter P; Kamyar MR; Peterbauer T; Berger W; Lemmens-Gruber R
    Chem Res Toxicol; 2007 Mar; 20(3):465-73. PubMed ID: 17326668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taiwanin A induced cell cycle arrest and p53-dependent apoptosis in human hepatocellular carcinoma HepG2 cells.
    Ho PJ; Chou CK; Kuo YH; Tu LC; Yeh SF
    Life Sci; 2007 Jan; 80(5):493-503. PubMed ID: 17182066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential role of diphenyleneiodonium, a flavoenzyme inhibitor, on p53-dependent and -independent cell cycle progression.
    Song JD; Kim KM; Kim KH; Kim CD; Kim JM; Yoo YH; Park YC
    Int J Oncol; 2008 Dec; 33(6):1299-306. PubMed ID: 19020764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.